- Why Cryoport
- Who We Serve
- About Us
- News & Events
- Investor Relations
- Contact Us
|Richard J. Berman* (Chair)|
|Robert Hariri, M.D., Ph.D.|
|Edward J. Zecchini|
|*Audit Committee Financial Expert|
|Richard J. Berman (Chair)|
|Robert Hariri, M.D., Ph.D.|
|Edward J. Zecchini|
|Nomination and Governance Committee|
|Edward J. Zecchini (Chair)|
|Richard J. Berman|
|Ramkumar Mandalam, Ph.D.|
|Scientific and Technology Committee|
|Robert Hariri, M.D., Ph.D.|
Chairman, President and Chief Executive Officer
Jerrell W. Shelton became a member of the Cryoport’s board of directors in October 2012 and was appointed president and chief executive officer in November 2012. Shelton has more than 30 years of executive and corporate governance experience across several industries including information services, telecommunications, manufacturing and distribution. Previously, he was a visiting executive at IBM Research, where his team created and developed WebFountain, a project contributing significantly to IBM’s software strategy. He was also president and CEO of NDC Holdings, Continental Graphics Holdings, Thomson Business Information Group and Advantage Companies. Under his leadership, each of those companies achieved rapid revenue growth, improved profitability and increased shareholder value. Shelton holds a B.S.B.A. degree from the University of Tennessee and an MBA from Harvard Business School.
Lead Director, Audit Committee Chair, Compensation Committee Chair, Nomination and Governance Committee
Richard Berman joined the Cryoport board in January 2015. Berman’s business career spans more than 35 years of venture capital, senior management and merger and acquisitions experience. In the past five years, Berman has served as a director and/or officer of more than a dozen public and private companies. From 2006 to 2011, he was chairman of National Investment Managers, a company with $12 billion in pension administration assets. Berman is a director of four public health care companies: Advaxis, Neostem, MetaStat and Cryoport. From 2002 to 2010, he was a director of Nexmed (now called Apricus Biosciences), where he also served as chairman/CEO in 2008 and 2009. He was chairman and CEO of Internet Commerce Corporation (now Easylink Services) from 1998 to 2000, and director from 1998 to 2012.
Previously, Berman worked at Goldman Sachs; was senior vice president of Bankers Trust Company, where he started the M&A and leveraged buyout departments; created the largest battery company in the world in the 1980s by merging Prestolite, General Battery and Exide to form Exide Technologies (XIDE); helped create what is now SoHo (Lower Manhattan, New York City) by developing five buildings; and advised on more than $4 billion of M&A transactions through the completion of more than 300 deals. He is formerly the director of the Stern School of Business of New York University, where he obtained his bachelor’s and MBA. He also has US and foreign law degrees from Boston College and The Hague Academy of International Law.
Director, Audit Committee, Scientific and Technology Committee
Robert Hariri became a member of the company’s board of directors in October 2015. He is the chairman, founder and chief scientific officer of Celgene Cellular Therapeutics, one of the world’s largest human cellular therapeutics companies and wholly owned subsidiary of Celgene Corporation. He has pioneered the use of stem cells and biomaterials to treat a range of life threatening diseases and has made transformative contributions in the field of tissue engineering.
Hariri has more than 100 issued and pending patents; has authored more than 100 published chapters, articles and abstracts; and is most recognized for his discovery of pluripotent stem cells from the placenta, and as a member of the team that discovered the physiological activities of tumor necrosis factor.
Hariri is also co-founder and president of Human Longevity Cellular Therapeutics, a leader in genomics and cellular technology. He is founder and chairman of Myos Corporation, located in Cedar Knolls, N.J., an emerging bio-therapeutics and bio-nutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and chronic and acute muscle diseases.
Hariri also serves on numerous boards of directors, including Myos Corporation, Bionik Laboratories and Provista Diagnostics. Hariri is a member of the scientific advisory board for the Archon X PRIZE for Genomics, which is awarded by the X PRIZE Foundation. He is also a member of the board of trustees of the J. Craig Venter Institute, a trustee of the Liberty Science Center and has been appointed commissioner of the New Jersey Commission on Cancer Research.
Hariri was the recipient of the Thomas Alva Edison Award in 2007 and 2011 and the Fred J. Epstein Lifetime Achievement Award and has received numerous other honors for his many contributions to biomedicine and aviation. He is an adjunct associate professor of pathology at the Mount Sinai School of Medicine and served as a member of the board of visitors of his alma mater, Columbia University School of Engineering & Applied Sciences and the Science & Technology Council of the College of Physicians and Surgeons. Hariri was awarded his M.D. and Ph.D. degrees from Cornell University Medical College and received his surgical training at The New York Hospital-Cornell Medical Center. He also directed the Aitken Neurosurgery Laboratory and the Center for Trauma Research.
Director, Compensation Committee, Nomination and Governance Committee
Ramkumar Mandalam joined the company's board of directors in 2014. Mandalam is the president and CEO of Cellerant Therapeutics, a clinical stage biotechnology company developing novel cell-based and antibody therapies for cancer treatment and blood-related disorders. Prior to joining Cellerant in 2005, he was the executive director of product development at Geron Corporation, a biopharmaceutical company where he managed the development and manufacturing of cell-based therapies for the treatment of degenerative diseases and cancer. From 1994 to 2000, he held various positions in research and development at Aastrom Biosciences, where he was responsible for programs involving ex vivo expansion of human bone marrow stem cells and dendritic cells. The author or co-author of several publications, patent applications and abstracts, Mandalam received his Ph.D. in chemical engineering from the University of Michigan.
Director, Audit Committee, Compensation Committee, Nomination and Governance Committee Chair
Edward Zecchini became a member of the board on Sept. 13, 2013, and currently serves as chief information officer at Remedy Partners. Prior to that, Zecchini served as executive vice president and chief technology officer at Sandata Technologies from May 2010 to March 2014, president and chief executive officer of IT Analytics from March 2008 to April 2010, executive vice president of operations and chief information officer of Touchstone Healthcare Partnership from May 2007 to February 2008 and senior vice president and chief information officer of HealthMarkets from October 2004 to April 2007. Earlier in his career, he held senior-level positions at Thomson Healthcare and SportsTicker. Zecchini has more than 30 years of experience in the health care and information technology industries. Zecchini holds a Bachelor of Arts degree from the State University of New York at Oswego.
"I want to thank everyone at Cryoport who was involved in the rapid recovery of the missing Cryoport shipper containing a patient’s tumor tissue. By promptly locating the shipper and recharging it while in transit, the patient was able to receive the vaccine manufactured from this tissue on time. We are so very appreciative of Cryoport’s customer service. Without the services that Cryoport provides, our clinical trials would not be available to patients."
“Working with Cryoport was a truly remarkable difference compared to my experience with other shippers. With the previous shipping company I was working with, it took almost three months to establish a ‘deep frozen account’ and required numerous hoop-jumping shenanigans only to ultimately be informed that the company could not arrange a shipment to or from Israel, which they were informed from the start was our desired shipping source.
Our sales rep at this organization was as dumbfounded by our experience as we were. To his credit, after his company declined our business, he suggested I contact Cryoport. I have written thanking him for his suggestion and to let his ‘powers-that-be’ know how different my experiences were.”